What is Cyprotex?
Cyprotex operates as a specialized research organization dedicated to advancing pharmaceutical development through comprehensive preclinical analysis. The company provides essential scientific services that evaluate how potential drug candidates behave within biological systems, examining their absorption, distribution, metabolism, and pharmacokinetic properties. This expertise is fundamental for pharmaceutical companies seeking to understand drug behavior before advancing candidates into clinical trials. By conducting rigorous preclinical assessments, Cyprotex enables informed decisions about which candidates warrant further investment, thereby reducing uncertainty in early-stage drug programs and supporting more efficient resource allocation. The organization serves pharmaceutical companies, biotechnology firms, and contract research organizations requiring detailed characterization of drug candidates' biological behavior.
How much funding has Cyprotex raised?
Cyprotex has raised a total of $10.8M across 1 funding round:
Debt
$10.8M
Debt (2013): $10.8M with participation from Harwood Capital
Key Investors in Cyprotex
Harwood Capital
Harwood Capital is an investment management firm specializing in public and private equities, known for its active engagement in portfolio companies. Their focus on generating significant returns aligns with strategic investments in companies poised for growth.
What's next for Cyprotex?
The recent major strategic investment in Cyprotex signals a strong confidence in its preclinical analysis capabilities and its contribution to the pharmaceutical development pipeline. This capital infusion is expected to fuel further expansion of its scientific services, potentially enhancing its analytical methodologies and broadening its research capacity. As the pharmaceutical industry continues to seek efficient and reliable methods for drug candidate evaluation, Cyprotex is strategically positioned to capitalize on this demand, driving innovation in early-stage drug discovery and development.
See full Cyprotex company page
